1. Scrip
  2. >>New Products

Horizon Provides Assurances That Tepezza Sales Are Set To Soar

Guidance Maintained For 30% Growth In 2022

 
• By Mandy Jackson

Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights. 

Red-tailed Hawk flying over the mountains with sky background
Horizon expects more than 30% Tepezza sales growth in 2022 • Source: Shutterstock

COVID-19 continues to put pressure on Horizon Therapeutics plc’s Tepezza (teprotumumab), which quickly generated blockbuster-level sales despite its pandemic-era launch but experienced a sequential decline in sales during the first quarter. However, while the Omicron variant affected Q1 sales, the company is maintaining its guidance for mid-30% growth in 2022 and further investing in its commercial team to capitalize on recent thyroid eye disease (TED) market insights.

Horizon generated impressive results for Tepezza (teprotumumab) to date with $820m in 2020 sales after its launch in February of that year and $1.66bn in 2021 sales despite a pandemic-related manufacturing disruption from December 2020 to March 2021 that resulted in just $2.1m in Q1 sales last year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

More from Scrip

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.